MCL Featured Stories

Tropical Storm Helene is approaching the Florida Gulf Coast and is expected to become a hurricane. These weather conditions may impact areas in the United States, including Alabama, Florida, Georgia, and South Carolina. We continue to monitor and track the situation with our logistics partners to minimize challenges. Clients in the affected areas should expect to be contacted directly if any routes are modified or canceled.

Founded in 2017, Mayo Clinic's Advanced Diagnostics Laboratory is a visionary space. In 2021, the lab developed the Mayo Complete Solid Tumor Panel, a clinically validated assay that analyzes 515 genes using next-generation sequencing. This multiple test panel, the first of its kind at Mayo, aids in selecting targeted therapies, diagnosing tumor types, and predicting prognosis, significantly improving patient care.

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

When Samantha Duke discovered she had breast cancer, she didn’t have to look far for support. Her mother Jane walked a similar path 16 years earlier. Inspired both by her mom and the strong network of healthcare physicians and professionals on her team, Samantha remained positive throughout her treatment and is committed to advancing research on breast cancer.

Unexpected events in the laboratory are an inevitability of the profession. The difference in whether it is manageable or chaotic comes down to the steps taken beforehand. By proactively preparing, you can drastically reduce the number of unknown variables to continue laboratory and outreach operations under less-than-ideal circumstances.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Shannon Strader, a resident doctor in cellular therapy at Mayo Clinic in Rochester, MN, to discuss trailblazing new connections in medicine.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Aiming to advance understanding of hard-to-predict gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Thermo Fisher Scientific joined forces with Mayo Clinic and BioPharma Diagnostics to validate and gain U.S. regulatory clearance of a novel, automated assay aimed at detecting a biomarker associated with the progressive disease.

Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff.

Tropical Storm Francine is active in the Gulf of Mexico and is expected to develop into a hurricane. These weather conditions may impact areas in the United States, including Alabama, Arkansas, Louisiana, Mississippi, Tennessee, and Texas. We continue to monitor and track the situation with our logistics partners to minimize challenges. Clients in the impacted areas should expect to be contacted directly if any routes are modified or canceled.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Ewa Wysokinska, M.D., an assistant professor of medicine and consultant in the division of hematology and oncology at Mayo Clinic in Florida, to talk about clinical updates in thrombotic thrombocytopenic purpura.

This page lists updates posted to Mayo Clinic Labs during the month of August.